Regenerative Therapies Market Worth US$ 18.4B by 2022

(Newswire.net — June 13, 2017) New York, NY — According to the latest market report published by Persistence Market Research, titled ‘Global Market Study on Regenerative Therapies: Asia Pacific & Japan to Witness Highest Growth by 2022’, the global regenerative therapies market is expected to expand at a CAGR of 20.0% during the forecast period 2016 – 2022.     

Regenerative therapies entail the application of specific types of cells or cell products for diseased tissues or organs, which would ultimately help restore tissue and organ function. It also involves the possibility of growing tissues and organs in the laboratory and safely implanting them when the body cannot heal itself.

The global regenerative therapies market has been estimated to be valued at US$ 5,286.2 million by the end of 2015 and is projected to witness stable growth across all global regions, which is attributed to the rising demand for fulfilling unmet clinical needs for longer sustainability and faster outcome treatments within a shorter time span.     

The prime growth driver for the global regenerative therapies market is a deficiency in therapeutic requirements. Currently, government support for treatment of various diseases is increasing globally, through the formation and adoption of supportive legislative and policy initiatives, which also include sizeable investments in regenerative therapies for creating centers of excellence, research networks, manufacturing infrastructure, and commercialization centers, among others. Furthermore, increasing demand for tissue-cell and stem cell research technologies as well as the products developed from them, which are used for treating various chronic diseases having no permanent cure, are the other important factors driving growth of the global regenerative therapies market currently. However, an ongoing trend that has been witnessed in the market is the increasing shift of companies from manufacturing of synthetic drugs to evaluating opportunities for generating medicines from an individual’s own tissues and stem cells.  

On the basis of the application type, the market has been segmented into soft tissue repair, cardiovascular, dental, orthopedic, CNS disease treatment, and others (which includes diabetes, autonomous diseases, ocular, and oncology). Currently, a majority of the patients and surgeons globally prefer regenerative therapies for orthopedic, soft tissue repair, and cardiovascular problems.     

On the basis of the end user segment type, the market has been segmented into hospitals, ambulatory surgical centers, and educational institutes. Currently, hospitals are the most preferred option for patients globally.  

On the basis of region, the market has been segmented into North America, Latin America, Europe, Asia Pacific & Japan, and the MEA regions.   

Rising per capita healthcare expenditure and contribution to GDP, increasing funding & government support for the development of regenerative therapies, as well as surge in incidences of chronic diseases are major factors driving the growth of the global regenerative therapies market currently.

The absence of standard regulations and legislations is leading to the invasion of many local players in both the developed and emerging regions. Moreover, high gestation period and time-to-market due to lengthy clinical trials, a large number of product recall within a short span post-approval, and lack of financial backing by smaller firms are among the major factors hampering the growth of regenerative therapies market currently. 

Other trends driving the market growth include industry maturation, advancements in technology, and increasing demand for long-term results and shorter time therapeutic procedures by patients. However, the market is expected to observe regulatory re-establishment with an increase in regenerative procedures and standardization of therapies over the forecast period.

A sample of this report is available upon request @ http://www.persistencemarketresearch.com/samples/10598

This report assesses trends driving each market segment and offers analysis and insights about the potential of regenerative therapies in specific regions. North America market is estimated to dominate the overall regenerative therapies market, accounting for a maximum value share of the global market by the end of 2016. By 2022, North America and Europe markets are expected to account for over three-fourth revenue share of the global regenerative therapies market. In terms of value, North America is estimated to be the dominant market, expanding at a CAGR of 19.7% over the forecast period.

Some key companies covered in this report include Acelity L.P. Inc., Mesoblast Ltd., Nuo Therapeutics, Inc. (Cytomedix), Astellas Pharma US, Inc., Organovo Holdings Inc., Orgenesis Inc., Sanofi, Athersys, Inc., Shire Pharmaceuticals Limited, and Cytori Therapeutics Inc. These companies are primarily focused on enhancing their product portfolio through R&D and on the introduction of innovative and cost-effective regenerative therapies in order to gain higher market share and to strengthen their respective position in the global regenerative therapies market.

View Report Table of Contents, Figures, and Tables @ http://www.persistencemarketresearch.com/market-research/regenerative-therapies-market/toc